PofoliaShared via Pofolia

Cells· 2026Q1· Review

The Role of the Mammalian Target of Rapamycin in Microglial Phenotypic Polarization

Kaitlyn J. Partridge, Allison D. Ebert

Short summary

mTORC1 signaling amplifies microglial inflammatory responses, while mTORC2 promotes anti-inflammatory and neuroprotective programs, with effects varying by disease context.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Microglial phenotypes exist on a continuum, not just discrete M1/M2 states.
  • mTOR signaling, regulated by mTORC1 and mTORC2, influences microglial polarization.
  • mTORC1 generally amplifies inflammatory responses.
  • mTORC2 generally promotes anti-inflammatory and neuroprotective programs.
  • The specific effects of mTORC1 and mTORC2 depend on the disease context.

AI-generated from the title and abstract; the full text is not read.

Abstract

Microglia are adaptive immune cells that maintain central nervous system homeostasis and respond dynamically to injury, infection, and other neurological insults. While traditionally classified into resting, pro-inflammatory “M1”, and anti-inflammatory “M2” states, advances in multi-omic profiling technologies have established that microglial phenotypes exist along a multidimensional and context-dependent continuum. The mammalian target of rapamycin (mTOR), a central regulator of cellular metabolism, growth, survival, and protein synthesis, has emerged as a potential central mediator of these state transitions through distinct activities downstream of mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). In this review, we examine current evidence linking mTOR signaling to microglial phenotypic polarization and functional plasticity. Generally, evidence suggests that mTORC1 acts as a context-dependent amplifier of inflammatory responses, whereas mTORC2 promotes anti-inflammatory and neuroprotective programs; however, the effects of either complex vary according to disease context. Understanding the balance and coordination of mTORC1 and mTORC2 signaling programs may clarify mechanisms that underly chronic neuroinflammation and guide the development of targeted therapies for neuroinflammatory disorders including Alzheimer’s disease, stroke, and epilepsy.

The authors' abstract, as published at the source. Cells, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Neurology (Neuroscience)

NeurologyNeuroscience